Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Patrick John Finn, President and COO of Twist Bioscience Corporation (TWST), reported a non-discretionary sale of 1,840 shares of Twist common stock on 08/21/2025 at a price of $25.964 per share. The filing states these shares were sold solely to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units and were not discretionary trades by the reporting person. After the transaction, the reporting person beneficially owned 233,529 shares, which the filing notes includes shares acquired under the company’s Employee Stock Purchase Plan in an exempt transaction. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Finn on 08/25/2025.
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corporation (TWST), reported a sale of 521 shares of TWST common stock on 08/21/2025 at a price of $25.964 per share. The Form 4 notes the sale was a "sell to cover" transaction required to satisfy tax withholding upon vesting of Restricted Stock Units and not a discretionary trade. After the transaction the reporting person beneficially owned 103,306 shares directly. The form was signed by an attorney-in-fact, Kendra Fox, on 08/25/2025.
Twist Bioscience (TWST) filed a Form 144 reporting a proposed sale of 853 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $23,620.68 and an approximate sale date of 08/25/2025. The filing shows these 853 shares were acquired on 08/22/2025 upon restricted stock vesting as part of compensation and were paid for on 08/22/2025. The filer previously sold small blocks of common stock on 06/06/2025, 08/04/2025, and 08/21/2025 for gross proceeds of $7,143.66, $5,275.72, and $6,179.48 respectively. The notice includes the required representation that the seller is not aware of any undisclosed material adverse information.
The Form 144 filed for TWST reports a proposed sale of 2,716 shares of common stock through Fidelity Brokerage Services on 08/21/2025 with an aggregate market value of $70,518.77. The shares were acquired on 08/20/2025 via restricted stock vesting from the issuer and payment is noted as compensation. The filing also lists five sales by Emily M. Leproust in the past three months totaling 12,711 shares with combined gross proceeds of $398,886.65 on dates from 05/21/2025 through 08/04/2025. The notice includes the standard signature representation about absence of undisclosed material adverse information.
Form 144 filed for Twist Bioscience Corporation (TWST) reporting an intended sale of common stock. The notice shows 1,840 shares to be sold through Fidelity Brokerage Services with an aggregate market value of $47,774.13 and an approximate sale date of 08/21/2025. The shares were acquired on 08/20/2025 via restricted stock vesting and relate to compensation. The issuer has 60,360,925 shares outstanding per the form. Recent disposals by the same person, Patrick Finn, are listed: 1,877 shares (05/21/2025, $55,835.87), 209 shares (07/02/2025, $7,564.36), 2,232 shares (07/23/2025, $79,773.02), and 3,189 shares (08/04/2025, $90,453.11).
Twist Bioscience (TWST) filed a Form 144 disclosing a proposed sale of 619 common shares with an aggregate market value of $16,071.84, to be sold approximately on 08/21/2025 on NASDAQ. The shares were acquired on 08/20/2025 upon restricted stock vesting and were issued as compensation. The filer reports prior sales by the same person, Paula Green, totaling 3,174 shares across five transactions between 05/21/2025 and 08/04/2025, producing gross proceeds of $97,059.51. The filer certifies they are unaware of any undisclosed material adverse information about the issuer.
Twist Bioscience (TWST) Form 144 notice: An insider proposes to sell 918 shares of common stock through Fidelity Brokerage Services on 08/21/2025, with an aggregate market value of $23,835.14. The shares were acquired by restricted stock vesting on 08/20/2025 and are being sold as compensation. The issuer has 60,360,925 shares outstanding, making this proposed sale a very small portion of the outstanding shares. The filing also discloses prior insider sales by Adam Laponis of 936 shares on 05/21/2025 (gross proceeds $27,843.57) and 2,449 shares on 07/09/2025 (gross proceeds $93,419.31). The notice includes the standard insider certification that no undisclosed material adverse information is known to the seller.
Form 144 notice from Twist Bioscience (TWST) shows an insider sale filing for common stock. The filer plans to sell 238 shares via Fidelity Brokerage Services on NASDAQ with an aggregate market value of $6,179.48 and an approximate sale date of 08/21/2025. The shares were acquired on 08/20/2025 through restricted stock vesting and were received as compensation. The filing lists four prior small common-stock sales by Robert Werner totaling 1,492 shares between 05/21/2025 and 08/04/2025 with gross proceeds reported for each sale. The notice includes the standard certification that the signer is unaware of undisclosed material adverse information.
Twist Bioscience (TWST) insider sale notice: This Form 144 reports a proposed sale of 521 common shares by an insider through Fidelity Brokerage Services with an aggregate market value of $13,527.35. The company has 60,360,925 shares outstanding and the sale is planned for 08/21/2025 on NASDAQ.
The shares were acquired on 08/20/2025 by restricted stock vesting as compensation and became payable on the same date. The filer previously sold common shares in six transactions between 05/21/2025 and 08/04/2025, totaling 2,022 shares for gross proceeds of $60,115.91. The filer certifies no undisclosed material adverse information.
Artisan Partners and several affiliated entities report beneficial ownership of 5,061,033 shares of Twist Bioscience common stock, equal to 8.4% of the outstanding class based on 59,916,141 shares outstanding as of 05/01/2025. The filing shows shared voting power of 4,078,039 shares and no sole voting or dispositive power reported.
The shares were acquired for and are held on behalf of discretionary clients of Artisan Partners Limited Partnership. The filing includes a certification that the holdings are held in the ordinary course of business and were not acquired to change or influence control of the issuer. No other person is reported to have an economic interest above 5% in these shares.